Anaphylaxis News

WASHINGTON — An epinephrine nasal spray resulted in outcomes that were comparable with injections in pediatric patients, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Alpha-gal may have triggered idiopathic anaphylaxis in patients screened at a specialized allergy clinic, according to a letter published in Clinical and Translational Allergy.

The FDA has approved Xolair for the reduction of allergic reactions, including anaphylaxis, that may occur with exposure to one or more foods in children and adults with Immunoglobulin E-mediated food allergy.

Children who experienced food-induced anaphylaxis before age 3 years had greater odds for developing eating and sleeping disorders that could persist into adulthood, according to a study published in Pediatric Allergy and Immunology.

ARS Pharma continues to study the effectiveness and safety of its neffy epinephrine nasal spray as patients with allergies wait for an alternative to autoinjectors for anaphylaxis treatment.

Healio compiled the most-read news in allergy, asthma and immunology posted in January.

A joint task force has published an updated, evidence-based practice parameter for diagnosing and treating anaphylaxis in Annals of Allergy, Asthma & Immunology.

Insect venom was the cause of most cases of occupational anaphylaxis, followed by food, drugs and latex, according to a study published in Allergy.

Most EDs do not have specific guidelines for observation time following anaphylaxis, and the average duration depends largely on comorbidities and the type of hospital, according to a survey study.

An intranasal epinephrine spray produced pharmacokinetic and pharmacodynamic results that were comparable or superior to intramuscular injections, according to a study published in The Journal of Allergy and Clinical Immunology: Global.